【港股异动 | 生物医药股集体走强创新药优化审批方案发布行业有望迎来加速发展】智通财经APP获悉，生物医药股集体走强，截至发稿，药明合联(02268.

智通财经07-31

【港股异动 | 生物医药股集体走强创新药优化审批方案发布行业有望迎来加速发展】智通财经APP获悉，生物医药股集体走强，截至发稿，药明合联(02268.HK)涨8.58%，报16.7港元；药明生物(02269.HK)涨8.57%，报11.4港元；荣昌生物(09995.HK)涨7.24%，报14.22港元；科伦博泰生物-B(06990.HK)涨6.9%，报156.4港元；诺诚健华(09969.HK...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2455923635?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-07-31 11:48","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2455923635","market":"sh","top_or_hot":-1,"title":"【港股异动 | 生物医药股集体走强 创新药优化审批方案发布 行业有望迎来加速发展】智通财经APP获悉，生物医药股集体走强，截至发稿，药明合联(02268.","media":"智通财经","content":"<div>\n<p>【港股异动 | 生物医药股集体走强 创新药优化审批方案发布 行业有望迎来加速发展】智通财经APP获悉，生物医药股集体走强，截至发稿，药明合联(02268.HK)涨8.58%，报16.7港元；药明生物(02269.HK)涨8.57%，报11.4港元；荣昌生物(09995.HK)涨7.24%，报14.22港元；科伦博泰生物-B(06990.HK)涨6.9%，报156.4港元；诺诚健华(09969.HK...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=ganggu\">网页链接</a>\n\n</div>\n","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7x24快讯</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7x24快讯\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-31 11:48 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.zhitongcaijing.com/immediately.html?type=ganggu><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>【港股异动 | 生物医药股集体走强 创新药优化审批方案发布 行业有望迎来加速发展】智通财经APP获悉，生物医药股集体走强，截至发稿，药明合联(02268.HK)涨8.58%，报16.7港元；药明生物(02269.HK)涨8.57%，报11.4港元；荣昌生物(09995.HK)涨7.24%，报14.22港元；科伦博泰生物-B(06990.HK)涨6.9%，报156.4港元；诺诚健华(09969.HK...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=ganggu\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1610","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","article_id":"2455923635","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2455923635","pubTimestamp":1722397725,"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【港股异动 | 生物医药股集体走强 创新药优化审批方案发布 行业有望迎来加速发展】智通财经APP获悉，生物医药股集体走强，截至发稿，药明合联(02268.HK)涨8.58%，报16.7港元；药明生物(","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159992":"创新药","161726":"生物医药","399441":"生物医药","688331":"荣昌生物","688428":"诺诚健华","BK1610":"ETF&股票定投概念","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1688375341.USD":"贝莱德中国灵活股票基金","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","06978":"永泰生物-B","LU0823426480.USD":"法巴中国股票经典Dis","LU0043850808.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AD\" INC","BK1576":"医药外包概念","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","LU0039217434.USD":"HSBC GIF CHINESE EQUITY \"AD\" INC","09969":"诺诚健华","LU0516422952.EUR":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","LU0140636845.USD":"施罗德大中华区股票A Acc","09995":"荣昌生物","BK1574":"生物医药B类股","IE00B0JY6N72.USD":"PINEBRIDGE GLOBAL EMERGING MARKETS FOCUS EQUITY \"A\" (USD) ACC","LU0856984785.SGD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"ACH\" (SGDHDG) ACC","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","BK1583":"高瓴概念","SG9999002562.SGD":"LionGlobal Asia Pacific SGD","LU0196878994.USD":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU0819121731.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (USD) ACC","06990":"科伦博泰生物-B","LU1720050803.USD":"安联全方位中国股票基金","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","02268":"药明合联","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","02269":"药明生物","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC"},"translate_title":"[Hong Kong stocks changed, biopharmaceutical stocks collectively strengthened, innovative drug optimization approval plan was released, and the industry is expected to usher in accelerated development] Zhitong Finance APP learned that biopharmaceutical stocks collectively strengthened","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"161726":1,"399441":1,"688331":1,"688428":1,"02269":1,"02268":1,"09995":1,"09969":1,"06990":1,"06978":1},"content_text":"【港股异动 | 生物医药股集体走强 创新药优化审批方案发布 行业有望迎来加速发展】智通财经APP获悉，生物医药股集体走强，截至发稿，药明合联(02268.HK)涨8.58%，报16.7港元；药明生物(02269.HK)涨8.57%，报11.4港元；荣昌生物(09995.HK)涨7.24%，报14.22港元；科伦博泰生物-B(06990.HK)涨6.9%，报156.4港元；诺诚健华(09969.HK)涨4.39%，报4.52港元。","kind":null,"is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2455923635"}

【港股异动 | 生物医药股集体走强 创新药优化审批方案发布 行业有望迎来加速发展】智通财经APP获悉，生物医药股集体走强，截至发稿，药明合联(02268.

精彩评论

【港股异动 | 生物医药股集体走强创新药优化审批方案发布行业有望迎来加速发展】智通财经APP获悉，生物医药股集体走强，截至发稿，药明合联(02268.